<- Go Home
Icosavax, Inc.
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.
Market Cap
$777.8M
Volume
425.3K
Cash and Equivalents
$63.2M
EBITDA
-$103.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$70.0M
Profit Margin
N/A
52 Week High
$16.11
52 Week Low
$4.75
Dividend
N/A
Price / Book Value
3.30
Price / Earnings
-6.98
Price / Tangible Book Value
3.30
Enterprise Value
$556.7M
Enterprise Value / EBITDA
-5.49
Operating Income
-$105.9M
Return on Equity
42.23%
Return on Assets
-26.73
Cash and Short Term Investments
$229.2M
Debt
$8.1M
Equity
$232.4M
Revenue
N/A
Unlevered FCF
-$42.6M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium